Analyst Reco. ResMed, Inc.

Equities

RMD

US7611521078

Market Closed - Nyse Other stock markets 04:00:01 2024-04-19 pm EDT			5-day change	1st Jan Change
178.8 ^USD	+0.70%		-3.77%	+3.97%

Apr. 17	Wall St set for higher open on megacaps boost; earnings, Fed comments on tap	RE
Apr. 01	Needham Adjusts ResMed's Price Target to $224 From $180, Maintains Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Needham Adjusts ResMed's Price Target to $224 From $180, Maintains Buy Rating	Apr. 01	MT
Morgan Stanley Adjusts Resmed’s Price Target to AU$31.80 From AU$28.60, Keeps at Overweight	Mar. 05	MT
Evans & Partners Upgrades ResMed to Positive From Neutral, Price Target is AU$31	Mar. 04	MT
Powell, the paper tiger	Feb. 05
ANALYST RECOMMENDATIONS : Abbvie, Microsoft, Tesla, Alphabet, Booking...	Feb. 05
Mizuho Adjusts Price Target on ResMed to $215 From $195, Keeps Buy Rating	Jan. 30	MT
Oppenheimer Raises ResMed Price Target to $205 From $185, Maintains Outperform Rating	Jan. 30	MT
UBS Adjusts ResMed Price Target to $180 From $175, Maintains Neutral Rating	Jan. 25	MT
Oppenheimer Raises ResMed Price Target to $185 From $175, Maintains Outperform Rating	Jan. 25	MT
RBC Lifts Price Target on ResMed to $182 From $181, Cites 'Solid' Fiscal Q2 Results, Keeps Sector Perform Rating	Jan. 25	MT
RBC Cuts Price Target on ResMed to $181 From $200, Keeps Sector Perform Rating	Jan. 22	MT
JPMorgan Adjusts Price Target on ResMed to $195 From $160, Maintains Overweight Rating	Jan. 09	MT
Nvidia comes to Wall Street's rescue	Jan. 09
ANALYST RECOMMENDATIONS : Blackrock, Blackstone, Exxon Mobil, Netflix, Charles Schwab...	Jan. 09
Joe Biden and Xi Jinping almost made up	Nov. 16
ANALYST RECOMMENDATIONS : Abbvie, Burberry, Chevron, Cisco, M&S...	Nov. 16
North American Morning Briefing : Rate Decisions, -2-	23-10-30	DJ
Morgan Stanley Upgrades Resmed to Overweight From Equalweight, Adjusts Price Target to AU$26 From AU$27.70	23-10-30	MT
Morgan Stanley Upgrades ResMed to Overweight From Equalweight, Adjusts Price Target to $169 From $180	23-10-27	MT
RBC Trims Price Target on ResMed to $200 From $202, Keeps Sector Perform Rating	23-10-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ResMed, Inc. continues to make headway in the sleep market

December 11, 2023 at 05:55 am EST